MD | DC | VA
Our Goal: To become a Top 3 BioHealth Hub by 2023.
Driving Innovation and Entrepreneurship
- World–renowned research institutions and universities
- Influential policymakers and advocacy groups pioneering new health strategies
- World–leading infectious disease research and vaccine development
- Fastest growing region for healthcare companies in the U.S.
- Rated #1 in the nation for science and engineering talent
- Mission control for the National Cancer Moonshot Initiative
AN INTERVIEW WITH GSK’S CHRISTOPHER MADDOX, DIRECTOR OF SITE OPERATIONS MOCONNECT recently interviewed GSK’s Christopher Maddox, Director of Site Operations for The Slaoui Center for Vaccines Research in Rockville. The…
Five startups have been selected to participate in the inaugural M-1 Ventures health and fitness-focused accelerator program based at Johns Hopkins University.
Women Building Bio: the XX factor is a day long conference to recognize and learn from leading women in the bioscience industry as pioneers paving the path to success. These women have faced their own unique challenges and carved out lasting legacies.
This day will catalyze the formation of a diverse network. It is a convergence of academia and industry, men and women, researchers and innovators, professionals and decision-makers gathering together to build relationships. This day long conference provides extraordinary opportunities to exchange new ideas, highlight areas of bioscience and research opportunities, and find partners for future collaboration.
TEDCO’s 7th Annual Entrepreneur Expo will bring together all of Maryland’s entrepreneurial resources from across the state into one place, at one time.
You can expect to see 700+ of the region’s top entrepreneurs, small and large business executives, angel and venture capital investors, federal and state economic development officials, university leaders and legislators.
Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.
Raxibacumab is a fully human monoclonal antibody, which secured approval from the US Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis.
A startup that spun out of research at the University of Maryland School of Medicine was acquired 18 months after forming.